A systematic multitechnique approach for detection and characterization of reversible self-association during formulation development of therapeutic antibodies

Journal of Pharmaceutical Sciences

Volumn 102, Issue 1, 2013, Pages 62-72

  Esfandiary, Reza ^a   Hayes, David B ^a   Parupudi, Arun ^a   Casas finet, Jose ^a   Bai, Shufeng ^a   Samra, Hardeep S ^a   Shah, Ambarish U ^a   Sathish, Hasige A ^a  

^a MEDIMMUNE   (United States)

Author keywords

Analytical ultracentrifugation; Biotechnology; Formulation; High throughput technologies; Intermolecular interaction; Light scattering (dynamic); Light scattering (static); Monoclonal antibody; Reversible self association; Screening

Indexed keywords

IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; OLIGOMER;

ANALYTIC METHOD; ARTICLE; DRUG FORMULATION; DYNAMIC LIGHT SCATTERING; LIGHT SCATTERING; MOLECULAR INTERACTION; MULTIANGLE STATIC LIGHT SCATTERING; PHARMACOLOGICAL PARAMETERS; REVERSIBLE SELF ASSOCIATION; ULTRACENTRIFUGATION;

EID: 84870660599     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23369     Document Type: Article

References (53)

1. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. 2005. Monoclonal antibody successes in the clinic. Nat Biotechnol 23(9):1073-1078.
2. Nelson AL, Dhimolea E, Reichert JM. 2010. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9(10):767-774.
3. Nissim A, Chernajovsky Y. 2008. Historical development of monoclonal antibody therapeutics. Handb Exp Pharmacol (181):3-18.
4. Dimitrov DS, Marks JD. 2009. Therapeutic antibodies: Current state and future trends-Is a paradigm change coming soon? Methods Mol Biol 525:1-27, xiii.
5. Reichert JM, Dhimolea E. 2012. The future of antibodies as cancer drugs. Drug Discov Today 17(17-18):954-963.
6. Presta LG. 2008. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20(4):460-470.
7. Dall'Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H. 2006. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol 177(2):1129-1138.
8. Jorgensen L, Hostrup S, Moeller EH, Grohganz H. 2009. Recent trends in stabilising peptides and proteins in pharmaceutical formulation-Considerations in the choice of excipients. Expert Opin Drug Deliv 6(11):1219-1230.
9. Wang W. 1999. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185(2):129-188.
10. Wang W, Singh S, Zeng DL, King K, Nema S. 2007. Antibody structure, instability, and formulation. J Pharm Sci 96(1):1-26.
11. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. 2010. Stability of protein pharmaceuticals: An update. Pharm Res 27(4):544-575.
12. Jezek J, Rides M, Derham B, Moore J, Cerasoli E, Simler R, Perez-Ramirez B. 2011. Viscosity of concentrated therapeutic protein compositions. Adv Drug Deliv Rev 63(13):1107-1117.
13. Saluja A, Kalonia DS. 2008. Nature and consequences of protein-protein interactions in high protein concentration solutions. Int J Pharm 358(1-2):1-15.
14. Liu J, Nguyen MD, Andya JD, Shire SJ. 2005. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci 94(9):1928-1940.
15. Yadav S, Liu J, Shire SJ, Kalonia DS. 2010. Specific interactions in high concentration antibody solutions resulting in high viscosity. J Pharm Sci 99(3):1152-1168.
16. Yadav S, Shire SJ, Kalonia DS. 2010. Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. J Pharm Sci 99(12):4812-4829.
17. Mason BD, Zhang L, Remmele Jr. RL, Zhang J. 2011. Opalescence of an IgG2 monoclonal antibody solution as it relates to liquid-liquid phase separation. J Pharm Sci 100(11):4587-4596.
18. Nishi H, Miyajima M, Nakagami H, Noda M, Uchiyama S, Fukui K. Phase separation of an IgG1 antibody solution under a low ionic strength condition. Pharm Res 27(7):1348-1360.
19. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93(6):1390-1402.
20. Li Y, Stafford WF, Hesselberg M, Hayes D, Wu Z, Byrne M. 2012. Characterization of the self-association of human interferon-alpha2b, albinterferon-alpha2b, and pegasys. J Pharm Sci 101(1):68-80.
21. Schellekens H. 2002. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1(6):457-462.
22. Clodfelter DK, Pekar AH, Rebhun DM, Destrampe KA, Havel HA, Myers SR, Brader ML. 1998. Effects of non-covalent self-association on the subcutaneous absorption of a therapeutic peptide. Pharm Res 15(2):254-262.
23. Philo JS, Arakawa T. 2009. Mechanisms of protein aggregation. Curr Pharm Biotechnol 10(4):348-351.
24. Gokarn YR, Fesinmeyer RM, Saluja A, Cao S, Dankberg J, Goetze A, Remmele RL Jr., Narhi LO, Brems DN. 2009. Ion-specific modulation of protein interactions: Anion-induced, reversible oligomerization of a fusion protein. Protein Sci 18(1):169-179.
25. Cromwell ME, Hilario E, Jacobson F. 2006. Protein aggregation and bioprocessing. AAPS J 8(3):E572-E579.
26. Nezlin R. 2010. Interactions between immunoglobulin G molecules. Immunol Lett 132(1-2):1-5.
27. Sule SV, Cheung JK, Antochshuk V, Bhalla AS, Narasimhan C, Blaisdell S, Shameem M, Tessier PM. 2012. Solution pH that minimizes self-association of three monoclonal antibodies is strongly dependent on ionic strength. Mol Pharmaceutics 9(4):744-751.
28. Gottschalk M, Nilsson H, Roos H, Halle B. 2003. Protein self-association in solution: The bovine beta-lactoglobulin dimer and octamer. Protein Sci 12(11):2404-2411.
29. Snoussi K, Halle B. 2005. Protein self-association induced by macromolecular crowding: A quantitative analysis by magnetic relaxation dispersion. Biophys J 88(4):2855-2866.
30. Adamczyk M, Moore JA, Rege SD, Yu Z. 1999. Investigations into self-association of vancomycin covalent dimers using surface plasmon resonance technology. Bioorg Med Chem Lett 9(16):2437-2440.
31. Ney A, Booms P, Epple G, Morgelin M, Guo G, Kettelgerdes G, Gessner R, Robinson PN. 2006. Calcium-dependent self-association of the C-type lectin domain of versican. Int J Biochem Cell Biol 38(1):23-29.
32. Nishi H, Miyajima M, Wakiyama N, Kubota K, Hasegawa J, Uchiyama S, Fukui K. 2011. Fc domain mediated self-association of an IgG1 monoclonal antibody under a low ionic strength condition. J Biosci Bioeng 112(4):326-332.
33. Gottschalk M, Venu K, Halle B. 2003. Protein self-association in solution: The bovine pancreatic trypsin inhibitor decamer. Biophys J 84(6):3941-3958.
34. Hassiepen U, Federwisch M, Mulders T, Lenz VJ, Gattner HG, Kruger P, Wollmer A. 1998. Analysis of protein self-association at constant concentration by fluorescence-energy transfer. Eur J Biochem 255(3):580-587.
35. Chitta RK, Gross ML. 2004. Electrospray ionization-mass spectrometry and tandem mass spectrometry reveal self-association and metal-ion binding of hydrophobic peptides: A study of the gramicidin dimer. Biophys J 86(1 Pt 1):473-479.
36. Sule SV, Sukumar M, Weiss WFt, Marcelino-Cruz AM, Sample T, Tessier PM. 2011. High-throughput analysis of concentration-dependent antibody self-association. Biophys J 101(7):1749-1757.
37. Howlett GJ, Minton AP, Rivas G. 2006. Analytical ultracentrifugation for the study of protein association and assembly. Curr Opin Chem Biol 10(5):430-436.
38. Attri AK, Minton AP. 2005. New methods for measuring macromolecular interactions in solution via static light scattering: Basic methodology and application to nonassociating and self-associating proteins. Anal Biochem 337(1):103-110.
39. Attri AK, Minton AP. 2005. Composition gradient static light scattering: A new technique for rapid detection and quantitative characterization of reversible macromolecular hetero-associations in solution. Anal Biochem 346(1):132-138.
40. Minton AP 1995. A molecular model for the dependence of the osmotic pressure of bovine serum albumin upon concentration and pH. Biophys Chem 57(1):65-70.
41. Scherer TM, Liu J, Shire SJ, Minton AP. 2010. Intermolecular interactions of IgG1 monoclonal antibodies at high concentrations characterized by light scattering. J Phys Chem B 114(40):12948-12957.
42. Brown JC, Pusey PN. 1975. Photon correlation study of polydisperse samples of polystyrene in cyclohexane. J Chem Phys 62:1136-1144.
43. Stafford WF, Sherwood PJ. 2004. Analysis of heterologous interacting systems by sedimentation velocity: Curve fitting algorithms for estimation of sedimentation coefficients, equilibrium and kinetic constants. Biophys Chem 108(1-3):231-243.
44. Theisen AC, Johann C, Deacon MP, Harding SE. 2000. Refractive increment data-book. Nottingham, UK: Nottingham University Press.
45. Saito S, Hasegawa J, Kobayashi N, Kishi N, Uchiyama S, Fukui K. 2012. Behavior of monoclonal antibodies: Relation between the second virial coefficient (B (2)) at low concentrations and aggregation propensity and viscosity at high concentrations. Pharm Res 29(2):397-410.
46. Alford JR, Kendrick BS, Carpenter JF, Randolph TW. 2008. Measurement of the second osmotic virial coefficient for protein solutions exhibiting monomer-dimer equilibrium. Anal Biochem 377(2):128-133.
47. Minton AP. 2007. The effective hard particle model provides a simple, robust, and broadly applicable description of nonideal behavior in concentrated solutions of bovine serum albumin and other nonassociating proteins. J Pharm Sci 96(12):3466-3469.
48. Minton AP, Edelhoch H. 1982. Light scattering of bovine serum albumin solutions: Extension of the hard article model to allow for electrostatic repulsion. Biopolymers 21:451-458.
49. Saluja A, Fesinmeyer RM, Hogan S, Brems DN, Gokarn YR. 2010. Diffusion and sedimentation interaction parameters for measuring the second virial coefficient and their utility as predictors of protein aggregation. Biophys J 99(8):2657-2665.
50. He F, Woods CE, Becker GW, Narhi LO, Razinkov VI. High-throughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations. J Pharm Sci 100(12):5126-5141.
51. Salinas BA, Sathish HA, Bishop SM, Harn N, Carpenter JF, Randolph TW. 2010. Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation. J Pharm Sci 99(1):82-93.
52. Shire SJ. 2009. Formulation and manufacturability of biologics. Curr Opin Biotechnol 20(6):708-714.
53. Samra HS, He F. 2012. Advancements in high throughput biophysical technologies: Applications for characterization and screening during early formulation development of monoclonal antibodies. Mol Pharm 9(4):696-707.